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Chronic calorie restriction has been known for decades to prevent or 
retard cancer growth, but its weight-loss 
effect and the potential problems associ-
ated with combining it with chemother-
apy have prevented its clinical application. 
Based on the discovery in model organ-
isms that short term starvation (STS or 
fasting) causes a rapid switch of cells to 
a protected mode, we described a fasting-
based intervention that causes remarkable 
changes in the levels of glucose, IGF-I and 
many other proteins and molecules and is 
capable of protecting mammalian cells 
and mice from various toxins, includ-
ing chemotherapy. Because oncogenes 
prevent the cellular switch to this stress 
resistance mode, starvation for 48 hours 
or longer protects normal yeast and mam-
malian cells and mice but not cancer cells 
from chemotherapy, an effect we termed 
Differential Stress Resistance (DSR). In 
a recent article, ten patients who fasted 
in combination with chemotherapy, 
reported that fasting was not only fea-
sible and safe but caused a reduction in a 
wide range of side effects accompanied by 
an apparently normal and possibly aug-
mented chemotherapy efficacy. Together 
with the remarkable results observed in 
animals, these data provide preliminary 
evidence in support of the human applica-
tion of this fundamental biogerontology 
finding, particularly for terminal patients 
receiving chemotherapy. Here we briefly 
discuss the basic, pre-clinical and clinical 
studies on fasting and cancer therapy.
After decades of slow progress in the iden-
tification of treatments effective on a wide 
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range of malignancies, cancer treatment 
is now turning to personalized therapies 
based in part on pharmacogenomics. By 
contrast, aging research is moving in the 
opposite direction by searching for com-
mon ways to prevent, postpone and treat 
a wide range of age-related diseases, based 
on the modulation of genetic pathways 
that are conserved from yeast to mam-
mals.1 In fact, it may be a solid evolution-
ary and comparative biology-foundation, 
which makes this ambitious goal of bio-
gerontologists a realistic or at least a prom-
ising one. On the other hand, the progress 
of biogerontology is viewed by many cli-
nicians as too fundamental and far from 
translational applications. In most cases, 
it is not clear how aging research will be 
translated into FDA approved drugs or 
treatments that have effects that are supe-
rior to those already available or being 
developed. For example, it is not clear how 
the long-term 20–30% reduction in calo-
rie intake (dietary restriction, DR) that 
we and many others before us have shown 
to be effective in extending the life span 
of model organisms will make humans 
live longer or healthier.1-3 Furthermore, 
despite the fact that long-term DR was 
confirmed to reduce cancer and cardiovas-
cular disease in monkeys4 and to be effec-
tive in preventing obesity, type 2 diabetes, 
inflammation, hypertension and athero-
sclerosis, as indicated by the early results 
in humans studies,5 it is highly unlikely to 
be adopted in its more extreme and effec-
tive version by even a small portion of the 
population. For example, the 20 to 40% 
chronic reduction in daily calorie intake 
shown to be effective in retarding cancer 
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contribute to DSR, much of it appears to 
be dependent on protective systems which 
are normally maintained in an inactive 
or low activity state even in non-dividing 
cells.1,25 In fact, in non-dividing yeast and 
mice, deficiencies in glucose or IGF-I sig-
naling that match those observed after 
starvation promote resistance to doxorubi-
cin, a chemotherapy drug that specifically 
targets muscle cells in the heart.21,22
As expected, many clinicians were 
skeptical of our hypothesis that cancer 
treatment could be improved not by a 
“magic bullet” but by a “not so magic DSR 
shield” as underlined by Leonard Saltz, an 
oncologist at Memorial Sloan-Kettering 
Cancer Center: “Would I be enthusias-
tic about enrolling my patients in a trial 
where they’re asked not to eat for 2.5 days? 
No.”26 However, ten oncologists did allow 
their patients, suffering from malignan-
cies ranging from stage II breast cancer 
to stage IV esophageal, prostate and lung 
malignancies to undergo a 48–140 hours 
pre-chemotherapy and a 5–56 hours post 
also as an attempt to achieve a much 
more potent therapeutic effect than that 
achieved by DR.17,18 Because starvation-
induced protection can increase many 
fold when combined with modulation 
of pro-aging pathways and since it is in 
principle blocked by the expression of any 
oncogene, it has the potential to provide a 
method to allow common chemotherapy 
to selectively kill cancer cells, indepen-
dently of the type of cancer.19-21 The DSR 
experiments in mammals were also based 
on our hypothesis that stress resistance 
and aging regulatory pathways were con-
served from yeast to mammals.
We found that fasting for 48 or more 
hours or in vitro starvation conditions that 
mimic fasting protected mice and/or nor-
mal cells but not cancer cells from various 
chemotherapy drugs and other deleterious 
agents.21 This effect was shown to depend 
in part on the reduction of circulating 
IGF-I and glucose levels.21,22 Although a 
differential regulation of cell division in 
normal and cancer cells23,24 is likely to 
growth in mice would not be feasible 
for cancer therapy for multiple reasons: 
(1) the effects of chronic DR in patients 
with a clinically evident tumor is expected 
to delay but not stop the progression of 
the disease6-8 and this delay may only 
occur for a portion of the malignancies,9 
(2) although weight loss and cachexia 
in the early stages of treatment are less 
prevalent than commonly thought,10-12 
the ~15% loss of BMI and ~30% long-
term loss of body fat caused by a moderate 
(20%) calorie restriction13 may be toler-
ated by only a very small portion of cancer 
patients receiving treatment, (3) Because 
this long-term restriction is accompanied 
by delayed wound healing and immuno-
logic impairment in rodents,1,14,15 it is not 
clear what risks it may impose on can-
cer patients receiving treatment.16 Our 
studies of DSR, which were triggered by 
our fundamental findings that switch-
ing yeast cells to water protected them 
against a wide range of toxins, started 
as a way to address these concerns but 
Figure 1. Average self-reported severity of symptoms in patients that have received chemotherapy with or without fasting.
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fatigue, weakness and gastrointestinal side 
effects while fasting27 (Fig. 1). A trend for 
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In those patients whose cancer progres-
sion was assessed, chemotherapy was 
effective and in some cases it was highly 
effective.27 A clinical trial sponsored by 
the V-Foundation for Cancer Research, 
aimed at testing the safety and efficacy of 
a 24 hour fast in combination with che-
motherapy, is in its safety stage. Because 
it was originally limited to patients diag-
nosed with bladder cancer the clinical 
trial progressed slowly. However, its recent 
expansion to include patients receiving 
platinum-based chemotherapy (breast, 
ovarian, lung cancer), is expected to expe-
dite it. Conclusive results for the effect of a 
3–4 day fast on chemotherapy-dependent 
side effects and possibly therapeutic index 
are not expected to become available for 
several years. Even if a more modest effect 
than the 1,000-fold differential protection 
against oxidative stress and chemotherapy 
observed in normal and cancer-like yeast 
cells was achieved in humans, this method 
could result in long-term survival for many 
patients with metastatic cancers, particu-
larly those in which malignant cells have 
not acquired multidrug resistance.
Acknowledgements
Lizzia Raffaghello is a recipient of a My 
First AIRC Grant (MFAG) and Giovanna 
Bianchi is a recipient of a FIRC (Italian 
Foundation for Cancer Research) fel-
lowship. This study was also funded 
14. Kristan DM. Calorie restriction and susceptibility to 
intact pathogens. Age (Dordr) 2008; 30:147-56.
15. Reed MJ, Penn PE, Li Y, Birnbaum R, Vernon RB, 
Johnson TS, et al. Enhanced cell proliferation and 
biosynthesis mediate improved wound repair in refed, 
caloric-restricted mice. Mech Ageing Dev 1996; 
89:21-43.
16. Kim SK, Demetri GD. Chemotherapy and neutrope-
nia. Hematol Oncol Clin North Am 1996; 10:377-95.
17. Longo VD, Ellerby LM, Bredesen DE, Valentine JS, 
Gralla EB. Human Bcl-2 reverses survival defects in 
yeast lacking superoxide dismutase and delays death 
of wild-type yeast. J Cell Biol 1997; 137:1581-8.
18. Wei M, Fabrizio P, Madia F, Hu J, Ge H, Li LM, et 
al. Tor1/Sch9-regulated carbon source substitution is 
as effective as calorie restriction in life span extension. 
PLoS Genet 2009; 5:1-15.
19. Longo VD. Mutations in signal transduction pro-
teins increase stress resistance and longevity in yeast, 
nematodes, fruit f lies and mammalian neuronal cells. 
Neurobiol Aging 1999; 20:479-86.
20. Fabrizio P, Pozza F, Pletcher SD, Gendron CM, 
Longo VD. Regulation of longevity and stress resis-
tance by Sch9 in yeast. Science 2001; 292:288-90.
21. Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, 
Bianchi G, et al. Starvation-dependent differential 
stress resistance protects normal but not cancer cells 
against high-dose chemotherapy. Proc Natl Acad Sci 
USA 2008; 105:8215-20.
22. Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, 
Parrella E, et al. Reduced levels of IGF-I mediate 
differential protection of normal and cancer cells in 
response to fasting and improve chemotherapeutic 
index. Cancer Res 2010; 70:1564-72.
23. Blagosklonny MV, Darzynkiewicz Z. Cyclotherapy: 
Protection of normal cells and unshielding of cancer 
cells. Cell Cycle 2002; 1:375-82.
24. Blagosklonny MV, Pardee AB. Exploiting cancer 
cell cycling for selective protection of normal cells. 
Cancer Res 2001; 61:4301-5.
25. Longo VD, Lieber MR, Vijg J. Turning anti-ageing 
genes against cancer. Nat Rev Mol Cell Biol 2008; 
9:903-10.
26. Couzin J. Cancer research. Can fasting blunt che-
motherapy’s debilitating side effects? Science 2008; 
321:1146-7.
27. Safdie FM, Dorff T, Quinn D, Fontana L, Wei 
M, Lee C, et al. Fasting and cancer treatment in 
humans: A case series report. Aging (Albany NY) 
2009; 1:988-1007.
